New hope for kids with devastating brain diseases: experimental cell therapy aims to halt progression
NCT ID NCT02254863
Summary
This early-stage study is testing the safety of adding a special type of cell, derived from umbilical cord blood, to a standard cord blood transplant for children with rare inherited metabolic diseases that damage the brain. The goal is to see if delivering these cells directly into the spinal fluid can help protect the nervous system faster and slow disease progression. The study will enroll up to 40 children and young adults up to age 21 who have one of several specific disorders, like Krabbe disease or Tay-Sachs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27705, United States
Contact
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.